SciClone Pharmaceuticals is based in Shanghai, China. It has raised $50M in total funding. Latest round: Growth.
SciClone Pharmaceuticals funding overview
SciClone Pharmaceuticals is based in Shanghai, China. SciClone Pharmaceuticals has raised $50M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Growth announced in January 2004. The round record for SciClone Pharmaceuticals runs through 2004; nothing later has been disclosed. Investors on record include GL Capital Management GP Limited, Bank of China Group Investment Limited, CDH Investments, Ascendent Capital Partners, Boying. 5 distinct backers are named across the disclosed rounds.
SciClone Pharmaceuticals at a glance
Total raised
$50M
Latest round
Growth
Latest round date
January 2004
Headquarters
Shanghai, China
Notable investors
GL Capital Management GP Limited, Bank of China Group Investment Limited, CDH Investments, Ascendent Capital Partners, Boying
Frequently asked about SciClone Pharmaceuticals funding
How much has SciClone Pharmaceuticals raised?
SciClone Pharmaceuticals has raised $50M in total disclosed funding across the rounds on record.
Who has invested in SciClone Pharmaceuticals?
GL Capital Management GP Limited, Bank of China Group Investment Limited, CDH Investments, Ascendent Capital Partners, Boying are named among the investors backing SciClone Pharmaceuticals.
What was the latest SciClone Pharmaceuticals funding round?
The most recent disclosed round is a Growth, announced in January 2004.
Where is SciClone Pharmaceuticals based?
SciClone Pharmaceuticals is based in Shanghai, China.
When did SciClone Pharmaceuticals last raise?
The last disclosed SciClone Pharmaceuticals round closed in January 2004 at Growth.
Every SciClone Pharmaceuticals figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Shanghai at a similar stage.
Companies related to SciClone Pharmaceuticals (18)
